Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOCRYST PHARMACEUTICALS INC Director's Dealing 2019

Dec 19, 2019

31868_dirs_2019-12-19_bfdd4fe0-233d-45fd-aad1-d9f97ac53fac.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2019-12-17

Reporting Person: Barnes Alane P (Senior VP, Chief Legal Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-12-17 Emp. Stock Option (Right to Buy) $3.23 A 190000 Acquired 2029-12-17 Common Stock (190000) Direct

Footnotes

F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.